Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non‐small cell lung cancer

Autor: Dongsheng Yue, Zhou Yanling, Chen Chen, Jing Ma, Xianjun Fan, Changli Wang, Yue Li, Zhenfa Zhang, Weiran Liu, Chenguang Li, Yansong Huo, Bin Zhang, Shu-Yu He, Jun-Cheng Zhang, Hua Zhang, Dongjiang Tang, Ye Xin, Yu-Chen Ma
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
Lung Neoplasms
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
Carcinoma
Non-Small-Cell Lung
Internal medicine
Biomarkers
Tumor
medicine
Humans
Prospective Studies
cardiovascular diseases
Stage (cooking)
early detection
Lung cancer
Prospective cohort study
non‐small‐cell lung cancer
Early Detection of Cancer
medicine.diagnostic_test
Receiver operating characteristic
business.industry
nutritional and metabolic diseases
Original Articles
Biomarker
General Medicine
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Peripheral blood
respiratory tract diseases
030104 developmental biology
small nodules
030220 oncology & carcinogenesis
population characteristics
Biomarker (medicine)
Female
Original Article
circulating genetically abnormal cells
Non small cell
business
Fluorescence in situ hybridization
Zdroj: Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 11, Pp 3234-3242 (2020)
ISSN: 1759-7714
1759-7706
Popis: Background Circulating genetically abnormal cells (CACs) with specific chromosome variations have been confirmed to be present in non‐small cell lung cancer (NSCLC). However, the diagnostic performance of CAC detection remains unclear. This study aimed to evaluate the potential clinical application of the CAC test for the early diagnosis of NSCLC. Methods In this prospective study, a total of 339 participants (261 lung cancer patients and 78 healthy volunteers) were enrolled. An antigen‐independent fluorescence in situ hybridization was used to enumerate the number of CACs in peripheral blood. Results Patients with early‐stage NSCLC were found to have a significantly higher number of CACs than those of healthy participants (1.34 vs. 0.19; P
Workflow of circulating genetically abnormal cells enumeration. Circulating genetically abnormal cell detection in early stage non‐small‐cell lung cancer was feasible. Circulating genetically abnormal cell test has good stability and adaptability for different patient populations. Circulating genetically abnormal cells could be used as a promising noninvasive biomarker for the early diagnosis of NSCLC.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje